Table 1. Baseline characteristics.
| Characteristics | TACE-sorafenib group (n=115) | TACE-apatinib group (n=86) | P |
|---|---|---|---|
| Sex | 0.950 | ||
| Men | 104 (90.4) | 78 (90.7) | |
| Women | 11 (9.6) | 8 (9.3) | |
| Age (years) | 0.699 | ||
| <52 | 53 (46.1) | 42 (48.8) | |
| ≥52 | 62 (53.9) | 44 (51.2) | |
| AFP (ng/mL) | 0.528 | ||
| <400 | 51 (44.3) | 42 (48.8) | |
| ≥400 | 64 (55.7) | 44 (51.2) | |
| HBV status | 0.237 | ||
| Positive | 105 (91.3) | 74 (86.0) | |
| Negative | 10 (8.7) | 12 (14.0) | |
| Child-Pugh | 0.700 | ||
| Class A | 96 (83.5) | 70 (81.4) | |
| Class B | 19 (16.5) | 16 (18.6) | |
| Tumor size (cm) | 0.190 | ||
| <5 | 34 (29.6) | 33 (38.4) | |
| ≥5 | 81 (70.4) | 53 (61.6) | |
| Tumor number | 0.313 | ||
| Single | 35 (30.4) | 32 (37.2) | |
| Multiple | 80 (69.6) | 54 (62.8) | |
| Vascular invasion | 0.748 | ||
| Present | 71 (61.7) | 55 (64.0) | |
| Absent | 44 (38.3) | 31 (36.0) | |
| Distant metastasis | 0.915 | ||
| Present | 66 (57.4) | 50 (58.1) | |
| Absent | 49 (42.6) | 36 (41.9) | |
| Dose reduction | <0.001 | ||
| Present | 20 (17.4) | 46 (53.5) | |
| Absent | 95 (82.6) | 40 (46.5) | |
| Cycles of TACE | 3.5±1.9 | 3.2±1.7 | 0.224 |
| Duration of targeted drugs (months) | 10.1±6.8 | 8.6±5.8 | 0.090 |
Data are shown as numbers of events with percentages in parentheses or averages ± standard deviations. TACE, transarterial chemoembolization; AFP, alpha fetoprotein; HBV, hepatitis B virus.